These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 37341835

  • 1. Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.
    Zhou Y, Wang W, Lin Z, Lin T, Gong L.
    Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3615-3623. PubMed ID: 37341835
    [Abstract] [Full Text] [Related]

  • 2. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
    Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q.
    Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT.
    Sci Rep; 2018 May 30; 8(1):8367. PubMed ID: 29849166
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
    Isshiki Y, Ishikawa H, Mimura O.
    Jpn J Ophthalmol; 2016 Nov 30; 60(6):486-491. PubMed ID: 27503401
    [Abstract] [Full Text] [Related]

  • 7. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI, Shin HM, Lee SY, Lew H.
    Acta Ophthalmol; 2013 Mar 30; 91(2):e108-12. PubMed ID: 23425111
    [Abstract] [Full Text] [Related]

  • 8. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y, Yokoi N, Okamoto M, Ishikawa H, Komuro A, Kato H, Mimura O, Gomi F.
    Jpn J Ophthalmol; 2020 Jan 30; 64(1):45-53. PubMed ID: 31823132
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
    Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O.
    Br J Ophthalmol; 2003 Jan 30; 87(1):54-6. PubMed ID: 12488263
    [Abstract] [Full Text] [Related]

  • 10. Correlation between blepharospasm and psychological diseases: the anxiety, depression and sleep disorder study.
    Zhang HN, Gao Q, Xie JJ, Ye J.
    Int J Ophthalmol; 2024 Jan 30; 17(11):2007-2013. PubMed ID: 39559314
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J, Gourdeau A.
    J Neuroophthalmol; 2014 Sep 30; 34(3):233-6. PubMed ID: 24739994
    [Abstract] [Full Text] [Related]

  • 13. Relationship between various clinical outcome assessments in patients with blepharospasm.
    Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G.
    Mov Disord; 2009 Feb 15; 24(3):407-13. PubMed ID: 19053054
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Association Between Sleep Quality, Mood Status, and Ocular Surface Characteristics in Patients With Dry Eye Disease.
    Wu M, Liu X, Han J, Shao T, Wang Y.
    Cornea; 2019 Mar 15; 38(3):311-317. PubMed ID: 30614900
    [Abstract] [Full Text] [Related]

  • 16. Botulinum Neurotoxin Type a Injection Combined with Absorbable Punctal Plug Insertion: An Effective Therapy for Blepharospasm Patients with Dry Eye.
    Ndikumukiza M, Xiao YT, Ye YF, Wang JS, Peng X, Xie HT, Zhang MC.
    J Clin Med; 2023 Jan 22; 12(3):. PubMed ID: 36769526
    [Abstract] [Full Text] [Related]

  • 17. Dry eye syndrome in benign essential blepharospasm.
    Girard BC, Lévy P.
    J Fr Ophtalmol; 2019 Dec 22; 42(10):1062-1067. PubMed ID: 31733914
    [Abstract] [Full Text] [Related]

  • 18. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
    Choi MG, Yeo JH, Kang JW, Chun YS, Lee JK, Kim JC.
    Graefes Arch Clin Exp Ophthalmol; 2019 Feb 22; 257(2):331-338. PubMed ID: 30552510
    [Abstract] [Full Text] [Related]

  • 19. Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections.
    Yabumoto C, Osaki MH, Osaki T, Gameiro GR, Campos M, Osaki TH.
    Ophthalmic Plast Reconstr Surg; 2019 Feb 22; 39(5):475-478. PubMed ID: 36928309
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm.
    Yang H, Lu J, Zhao X, Ding X, Wang Z, Cai X, Luo Y, Lu L.
    J Ophthalmol; 2016 Feb 22; 2016():5957812. PubMed ID: 26885381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.